

Katsunobu Hagihara

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7226002/publications.pdf>

Version: 2024-02-01

24
papers

2,284
citations

759233

12
h-index

642732

23
g-index

24
all docs

24
docs citations

24
times ranked

2594
citing authors

#	ARTICLE	IF	CITATIONS
1	Identification of the Human Cytochrome P450 Enzymes Involved in the Two Oxidative Steps in the Bioactivation of Clopidogrel to Its Pharmacologically Active Metabolite. <i>Drug Metabolism and Disposition</i> , 2010, 38, 92-99.	3.3	711
2	DS-8201a, A Novel HER2-Targeting ADC with a Novel DNA Topoisomerase I Inhibitor, Demonstrates a Promising Antitumor Efficacy with Differentiation from T-DM1. <i>Clinical Cancer Research</i> , 2016, 22, 5097-5108.	7.0	599
3	Bystander killing effect of <sc>DS</sc>â€8201a, a novel antiâ€human epidermal growth factor receptor 2 antibodyâ€drug conjugate, in tumors with human epidermal growth factor receptor 2 heterogeneity. <i>Cancer Science</i> , 2016, 107, 1039-1046.	3.9	394
4	A Possible Mechanism for the Differences in Efficiency and Variability of Active Metabolite Formation from Thienopyridine Antiplatelet Agents, Prasugrel and Clopidogrel. <i>Drug Metabolism and Disposition</i> , 2009, 37, 2145-2152.	3.3	108
5	Clonal Deletion of Tumor-Specific T Cells by Interferon-Î³ Confers Therapeutic Resistance to Combination Immune Checkpoint Blockade. <i>Immunity</i> , 2019, 50, 477-492.e8.	14.3	93
6	Comparison of Human Cytochrome P450 Inhibition by the Thienopyridines Prasugrel, Clopidogrel, and Ticlopidine. <i>Drug Metabolism and Pharmacokinetics</i> , 2008, 23, 412-420.	2.2	70
7	Mechanism-Based Inhibition of Human Cytochrome P450 2B6 by Ticlopidine, Clopidogrel, and the Thiolactone Metabolite of Prasugrel. <i>Drug Metabolism and Disposition</i> , 2009, 37, 589-593.	3.3	54
8	Immunostimulatory oligodeoxynucleotide induces TH1 immune response and inhibition of IgE antibody production to cedar pollen allergens in mice. <i>Journal of Allergy and Clinical Immunology</i> , 1999, 104, 1231-1238.	2.9	32
9	Comparison of formation of thiolactones and active metabolites of prasugrel and clopidogrel in rats and dogs. <i>Xenobiotica</i> , 2009, 39, 218-226.	1.1	31
10	Pharmacokinetics of trastuzumab deruxtecan (T-DXd), a novel anti-HER2 antibody-drug conjugate, in HER2-positive tumour-bearing mice. <i>Xenobiotica</i> , 2020, 50, 1242-1250.	1.1	31
11	Biotransformation of Prasugrel, a Novel Thienopyridine Antiplatelet Agent, to the Pharmacologically Active Metabolite. <i>Drug Metabolism and Disposition</i> , 2010, 38, 898-904.	3.3	29
12	Neoadjuvant sipuleucel-T induces both Th1 activation and immune regulation in localized prostate cancer. <i>Oncimmunology</i> , 2019, 8, e1486953.	4.6	27
13	Component of Caramel Food Coloring, THI, Causes Lymphopenia Indirectly via a Key Metabolic Intermediate. <i>Cell Chemical Biology</i> , 2016, 23, 555-560.	5.2	14
14	Cross-platform comparison of immune-related gene expression to assess intratumor immune responses following cancer immunotherapy. <i>Journal of Immunological Methods</i> , 2021, 494, 113041.	1.4	13
15	Absorption, distribution and excretion of the new thienopyridine agent prasugrel in rats. <i>Xenobiotica</i> , 2007, 37, 788-801.	1.1	12
16	Glutaredoxin and Thioredoxin Can Be Involved in Producing the Pharmacologically Active Metabolite of a Thienopyridine Antiplatelet Agent, Prasugrel. <i>Drug Metabolism and Disposition</i> , 2011, 39, 208-214.	3.3	11
17	The Possible Mechanism of Idiosyncratic Lapatinib-Induced Liver Injury in Patients Carrying Human Leukocyte Antigen-DRB1*07:01. <i>PLoS ONE</i> , 2015, 10, e0130928.	2.5	11
18	The Intestine As an Important Contributor to Prasugrel Active Metabolite Formation In Vivo. <i>Drug Metabolism and Disposition</i> , 2011, 39, 565-570.	3.3	9

#	ARTICLE	IF	CITATIONS
19	Human Intestinal Raf Kinase Inhibitor Protein (RKIP) Catalyzes Prasugrel as a Bioactivation Hydrolase. <i>Drug Metabolism and Disposition</i> , 2015, 44, 115-123.	3.3	9
20	In Silico and In Vitro Analysis of Interaction between Ximelagatran and Human Leukocyte Antigen (HLA)-DRB1*07:01. <i>International Journal of Molecular Sciences</i> , 2017, 18, 694.	4.1	9
21	Interaction of Nevirapine with the Peptide Binding Groove of HLA-DRB1*01:01 and Its Effect on the Conformation of HLA-Peptide Complex. <i>International Journal of Molecular Sciences</i> , 2018, 19, 1660.	4.1	8
22	Glutaredoxin Is Involved in the Formation of the Pharmacologically Active Metabolite of Clopidogrel from Its GSH Conjugate. <i>Drug Metabolism and Disposition</i> , 2012, 40, 1854-1859.	3.3	7
23	Isolation of proliferation factor of immature T-cell clone in concanavalin A-stimulated splenocyte culture supernatant. <i>Immunology</i> , 2003, 109, 209-216.	4.4	2
24	Thienopyridine P2Y12 receptor antagonists: unknown pharmacological active metabolites and metabolic activation mechanisms. <i>Drug Delivery System</i> , 2015, 30, 454-464.	0.0	0